What are the side effects of Sotorasib?

Sotorasib, marketed under the brand name Lumakras, is a groundbreaking medication approved for the treatment of certain types of non-small cell lung cancer (NSCLC) harboring the KRAS G12C mutation. While it represents a significant advancement in cancer therapy, it's crucial to understand the potential side effects associated with its use.

The common side effects of Sotorasib can range from mild to moderate in severity. One of the most frequently reported issues is gastrointestinal discomfort, including diarrhea, nausea, and vomiting. These symptoms can often be managed with supportive care and medications to alleviate the discomfort.

Another common side effect is fatigue. Patients undergoing treatment with Sotorasib may experience varying degrees of tiredness, which can affect their daily activities. It is recommended to monitor energy levels and adjust activities accordingly, incorporating rest periods as needed.

Decreased appetite and weight loss are also notable side effects. It's important for patients to maintain a balanced diet and consult with a nutritionist if necessary to ensure they receive adequate nutrition during treatment.

Liver function abnormalities are another potential concern. Elevated liver enzymes have been observed in some patients taking Sotorasib. Regular monitoring of liver function tests is essential, and any significant changes should be discussed with the healthcare provider promptly.

Respiratory issues, such as cough and shortness of breath, have also been reported. These symptoms can be particularly concerning for patients with lung cancer, and any new or worsening respiratory problems should be evaluated by a healthcare professional.

A less common but serious side effect is interstitial lung disease (ILD). This condition involves inflammation and scarring of the lung tissue, which can lead to breathing difficulties. Patients should report any new respiratory symptoms immediately, as early detection and intervention are crucial for managing ILD.

Additionally, musculoskeletal pain, including back pain and joint pain, has been noted in some individuals taking Sotorasib. Pain management strategies, such as medications, physical therapy, and lifestyle modifications, can be beneficial in alleviating discomfort.

Lastly, certain patients may experience electrolyte imbalances, including low levels of potassium, calcium, and magnesium. Regular blood tests are essential to monitor electrolyte levels and ensure they remain within a healthy range.

In summary, while Sotorasib offers hope for patients with KRAS G12C-mutated NSCLC, it is accompanied by a range of potential side effects. By being aware of these side effects and working closely with healthcare providers, patients can better manage their symptoms and maintain their quality of life during treatment.